Skip to main content
RGNX logo

RGNX · REGENXBIO Inc. · Documents

Track RGNX — free
$7.16 -0.02 (-0.28%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$473.44M
Shares
66.12M
Volume · Nov 20 1.06M Avg daily vol (3M) 1.38M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $170.44M up 104.5% 10-K filed Mar 5, 2026 Quarterly report FY2026 Q3 Revenue $9.16M down 69.2% 10-Q filed Nov 5, 2026 Latest results RGX-202 BLA submission on track for Q1 2027 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 5
Earnings call
Suravec data and RGX202 filing loom with $251 million cash

Regenexx Bio said Suravec wet AMD pivotal data are expected this quarter, RGX202’s full BLA filing is planned for the first quarter of 2027, and cash, cash equivalents and marketable securities totaled $251 million at September 30, 2026.

5 source passages
Earlier this morning, Regenexx Bio released financial and operating results for the third quarter ended September 30, 2026. The SURAVEC pivotal top-line data expected this quarter could reshape the treatment paradigm for WET-AMD. Turning to RGX202, we continue to make meaningful progress towards bringing our potential best-in-class gene therapy for Duchenne to patients in the U.S. and beyond. Preparations are well underway to submit the BLA under the Accelerated Approval Pathway in the first quarter of 2027, supporting potential approval in the U.S. in the second half of 2027. Regenix file ended the third quarter of 2026 with cash, cash equivalent, and marketable securities of $251 million compared to $241 million as of December 31st, 2025. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Pivotal RGX-202 success contrasts with RGX-121 hold

REGENXBIO reported positive pivotal RGX-202 results and plans a BLA submission in the first quarter of 2027, while RGX-121 remains on clinical hold. The wet AMD pivotal program completed enrollment, with topline data expected in the fourth quarter of 2026.

Revenue $9.16M ▼ 69.2% Net loss $40.74M Diluted EPS -$0.62
Read from the MD&A section
5 source passages
In May 2026, we announced positive topline results from the pivotal Phase III AFFINITY DUCHENNE trial of RGX-202 Given the positive topline pivotal data, continued favorable safety profile, and statistically significant correlation between microdystrophin and functional improvement, we expect to hold a pre-Biologics License Application (BLA) meeting with the FDA in the fourth quarter of 2026 and submit a BLA in the first quarter of 2027 under the accelerated approval pathway, supporting potential FDA approval in the second half of 2027. In August 2026, we announced that the FDA placed a clinical hold on RGX-121 following the discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE study. Enrollment in the ATMOSPHERE and ASCENT pivotal trials for the treatment of patients with wet AMD using subretinal delivery was completed in October 2025. Topline data from these trials are expected to be announced in the fourth quarter of 2026 in partnership with AbbVie Open the document at this passage
Nov 5
Current report 8-K
RGX-202 BLA submission on track for Q1 2027

REGENXBIO remains on track to submit the RGX-202 BLA in Q1 2027, while reporting $251.0 million in cash, cash equivalents and marketable securities and a $40.7 million net loss for the third quarter ended September 30, 2026.

Financial results
4 source passages
Neuromuscular Disease: RGX-202 is a potential best-in-class gene therapy for Duchenne muscular dystrophy (Duchenne). The Company expects to have a pre-Biologics License Application (BLA) meeting with the FDA in Q4 2026 and is on track to submit a BLA in Q1 2027 under the accelerated approval pathway, supporting potential approval in 2H 2027. Cash, cash equivalents and marketable securities were $251.0 million as of September 30, 2026, compared to $240.9 million as of December 31, 2025. Net loss was $40.7 million, or $0.62 basic and diluted net loss per share, for the three months ended September 30, 2026, compared to a net loss of $61.9 million, or $1.20 basic and diluted net loss per share, for the three months ended September 30, 2025. Open the document at this passage
Oct 16
Current report 8-K Events of Oct 14
Kenneth T. Mills resigns from board; George Migausky named Chairman

Kenneth T. Mills resigned from the board effective October 21, 2026, to focus on his new role as chief executive officer of another company. The board appointed George Migausky as Chairman, and Daniel Tassé stepped down as Lead Independent Director but remains a board member.

Director or officer change, or executive pay
3 source passages
On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the “Board”) of REGENXBIO Inc. (the “Company”) effective October 21, 2026. In connection with Mr. Mills’ departure, the Board appointed George Migausky as Chairman of the Board (“Chairman”). In accordance with the Company’s Corporate Governance Guidelines, Daniel Tassé has stepped down from his position as Lead Independent Director, as the new Chairman is an independent director, but will remain a member of the Board. Open the document at this passage
Sep 23
Current report 8-K
Entered into a material agreement

On September 23, 2026, REGENXBIO Inc. entered a settlement with Sarepta that requires a $39.0 million payment to REGENXBIO within 10 days of the effective date and terminates all ongoing patent litigation over ELEVIDYS-related patents.

Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $108.02M ▲ 405.7% Net income $22.71M Diluted EPS $0.43
Jul 20
Current report 8-K Events of Jul 16
Other events AI summary on its way
Jul 6
Tender offer SC TO-I/A
Tender offer AI summary on its way
Jul 1
Tender offer SC TO-I/A
Tender offer AI summary on its way
Jun 29
Current report 8-K Events of Jun 23
Other events AI summary on its way
Jun 3
Tender offer SC TO-I
Tender offer AI summary on its way
May 14
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $6.39M ▼ 92.8% Net loss $90.05M Diluted EPS -$1.72
Apr 14
Proxy statement DEF 14A Meeting May 29, 2026
Proxy statement AI summary on its way
Apr 3
Proxy statement PRE 14A Meeting May 29, 2026
Proxy statement AI summary on its way
Mar 5
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $170.44M ▲ 104.5% Net loss $193.88M Diluted EPS -$3.76
Jan 28
Current report 8-K Events of Jan 23
Other events AI summary on its way
2025
Showing 1–50 of 160 documents
Key facts CIK 1590877 CUSIP 75901B107 13F (30d) 173 filings 157 filers Visit website Investor relations